Many human tumors express high levels of the p53 inhibitor Mdm2, resulting from amplification of the Mdm2 locus or aberrant post-translational regulation of the Mdm2 protein. While the importance of Mdm2 in regulating p53 is clear, Mdm2 also has p53-independent roles. For example, overexpression of Mdm2 results in genomic instability in a p53-independent manner. In addition, Mdm2 has many additional binding partners, some of which, such as the tumor suppressor p73, have also been implicated in genomic instability. In this study, cells and tumors with Mdm2 overexpression and p73 loss exhibit increased genomic instability as compared with either alteration alone and cooperate in development of B-cell lymphomagenesis. Cytogenetic analysis of mouse embryonic fibroblasts and pre-malignant B cells demonstrates that loss of p73 exacerbates the chromosome breaks and fusions observed in Mdm2
INTRODUCTION
The p53 pathway is altered in over 90% of human cancers by several mechanisms including mutation or deletion of the TP53 gene itself and overexpression of the p53 inhibitor, MDM2. Mdm2 is a RING finger-containing E3 ubiquitin ligase that targets p53 for proteasomal degradation. Loss of Mdm2 leads to an embryonic lethal phenotype that is p53-dependent. 1, 2 More relevant to human tumors is the finding that many tumors produce high levels of Mdm2 resulting from amplification of the Mdm2 locus or aberrant post-translational regulation of the MDM2 protein. 3 While the importance of Mdm2 in regulating p53 is clear, Mdm2 also has p53-independent roles. For example, overexpression of Mdm2 in one mouse model resulted in multiple rounds of DNA synthesis without cell division leading to polyploidy in a p53-independent manner in mammary epithelial cells, 4 and Mdm2 overexpression results in genomic instability in a p53-independent manner in NIH3T3 cells and mouse embryonic fibroblasts (MEFs). 5 
Mdm2
Tg mice that express two-to fourfold elevated Mdm2 levels are tumor prone and develop a different tumor spectrum from that of p53-null mice, 6 further supporting a p53-independent function of Mdm2 during tumorigenesis. In addition, analysis of these Mdm2 transgenic mice also showed genomic instability in primary pre-B cells, splenocytes and purified splenic B cells. 7 Mdm2 overexpression also enhances the increased genomic instability observed in aging mice, further supporting a role for Mdm2 overexpression in genomic instability. 8 In addition, Mdm2 has many other binding partners including the p53 family member, p73. 9 The TP73 gene expresses seven alternatively spliced C-terminal isoforms (TAp73), which contain a complete amino-terminal transactivation domain, and four N-terminal isoforms (ΔNp73), which lack the transactivation domain. A mouse deficient for all isoforms of p73 exhibits neurological and inflammatory defects, resulting in a high incidence of mortality in p73 − / − pups (80% of pups do not survive past 30 days). A p73 mouse heterozygous for all isoforms is tumor prone and, when combined with p53 deficiency, results in increased metastasis. 10 Mdm2 specifically binds the TAp73 isoforms with similar affinity to that of Mdm2 for p53. 11 Although Mdm2 is an E3 ubiquitin ligase, it does not target TAp73 for degradation, but blocks its transcriptional activation. 12, 13 The TAp73 isoforms can transactivate p53 targets such as Bax, Puma and p21 to induce apoptosis and cell cycle arrest. 14, 15 In addition, the TAp73 isoforms also have unique, p53-independent targets and cellular functions. For example, TAp73 plays a role in antioxidant metabolism through its direct activation of glucose-6-phosphate 1-dehydrogenase, the rate-limiting enzyme of a major glucose metabolic pathway (pentose phosphate pathway). 16 Furthermore, unlike p53-deficient mice, a TAp73-specific knockout mouse exhibits genomic instability in a cell-specific manner. 17 In contrast, loss of the ΔNp73 isoforms has no effect on genomic stability, but mice exhibit neurodegeneration. In addition, ΔNp73 inhibits p53 and TAp73 activity by competitive binding to the promoters of target genes such as Puma and p21 in both untreated cells and cells treated with a range of DNA-damaging agents. 18, 19 Consequently, MEFs and thymocytes from ΔNp73 − / − mice exhibit an enhanced apoptotic response. Lastly, E1A and Ras V12 -transformed ΔNp73 − / − MEFs injected into nude mice were unable to form tumors unlike wild-type E1A and Ras V12 -transformed MEFs, indicating the ΔNp73 isoforms are necessary for transformed cells to form tumors in vivo. 18 Given these data, the TAp73 isoforms are thought to have tumor suppressor functions and the ΔNp73 isoforms to have oncogenic functions. Despite the reported interaction between Mdm2 and TAp73, to date no studies have addressed the in vivo relevance or physiological consequence of this interaction. Given that Mdm2 has p53-independent functions, we propose that the oncogenic activity of Mdm2 is a combined effect of inhibiting p53 and p73 functions. Here, we present the first evidence that Mdm2 overexpression and p73 loss cooperate to induce genomic instability, resulting in accelerated spontaneous tumorigenesis.
Tg ;p73 +/ − mice develop a high incidence of B-cell lymphoma, a tumor type in humans know to have decreased p73 levels. [20] [21] [22] [23] Analysis of pre-malignant B cells reveals increased chromosome fusions in these mice. Furthermore, we show that B-cell lymphomas from Mdm2
Tg ;p73 +/ − mice exhibit deregulation of the B-cell antiapoptotic protein, Bcl2, and a dampened apoptotic response. Taken together, these data indicate that Mdm2 overexpression and p73 loss cooperate in genomic instability and result in accelerated B-cell lymphomagenesis.
RESULTS

Loss of p73 exacerbates genomic instability and results in increased growth of Mdm2
Tg MEFs
Given that Mdm2 can inhibit p73 transcriptional activity and that both overexpression of Mdm2 and loss of TAp73 have been implicated in genomic instability and tumor development, we first examined whether these two alterations may have an additive effect on genomic instability by examining metaphase spreads in Mdm2 Tg ;p73 +/ − and Mdm2 Tg ;p73 − / − MEFs. Mdm2 Tg transgenic mice were generated using a cosmid containing the entire Mdm2 gene and these mice express two-to fourfold elevated Mdm2 levels. 6 The p73-deficient mice are either heterozygous or null for all isoforms of p73.
10 Passage 1 MEFs were examined for chromosome abnormalities such as chromosome breaks, chromatid breaks, chromosome fragments and chromosome fusions. As previously reported, Mdm2 overexpression alone resulted in a small increase in chromosome breaks and fusions compared with wild-type MEFs, 5 but p73 loss does not ( Figure 1a ). In contrast, Mdm2 overexpression combined with loss of one copy or both copies of p73 results in more severe abnormalities (Figures 1a and b Tg and p73 +/ − MEFs begin to senescence at passage 3, as indicated by lack of proliferation, positive SA-β-GAL staining and morphological changes consistent with senescence (Figures 2a and b) . In addition, loss of p73 in an Mdm2
Tg background resulted in an increase in S and a decrease in G2M phases of the cell cycle by passage 3 as measured by flow cytometry using propidium iodide staining (Figure 2c ). 
Mdm2Tg;p73+/-Mdm2Tg
Mdm2
Tg ;p73 +/ − , p73 − / − and Mdm2 Tg ;p73 − / − mutant mice in a pure C57Bl/6 background for 2 years or until moribund. As previously reported, complete loss of p73 results in a high incidence of mortality in the first 3 months of life owing to developmental and immunological defects. 24 As a result, only a small cohort of p73 Tg ;p73 +/ − mice retained the wild-type copy of p73, indicating either that loss of one p73 allele in the Mdm2 Tg background is sufficient to accelerate lymphomagenesis or that Mdm2 overexpression dampens activity of the remaining allele.
To further characterize these B-cell lymphomas, we analyzed IgH rearrangements in tumor DNA by Southern blotting. Compared with wild-type spleen DNA, which contains a single germline band, all Mdm2
Tg , Mdm2 Tg ;p73 +/ − and p73 − / − B-cell lymphoma samples contained one to two rearranged bands (Figure 4d ). When possible, a peripheral lymph node from the same mouse was analyzed and found to contain identical IgH rearrangements as splenic tumors (lanes 6-7 and 11-12 Tg mice (8.5% vs 1.5%, respectively, Po 0.05) and a significantly higher percentage of cells with aberrant metaphases (42 abnormalities per cell) (19% vs 3.2%, respectively, P o0.05) (Figure 5a ). Examples of metaphases from purified B cells are shown in Figure 5b .
Tg mice with p73 loss exhibit increased Bcl2 protein expression Given the proliferative advantage in Mdm2 Tg ;p73 +/ − and Mdm2 Tg ; p73 − / − MEFs, we hypothesized that one or more apoptotic programs may be dampened in these animals contributing to development of B-cell lymphomagenesis. To investigate the potential mechanism(s) contributing to this phenotype, we considered apoptotic genes that are regulated by both p53 and p73. One candidate gene is the antiapoptotic oncogene Bcl2. Bcl2 is negatively regulated by p53 through direct binding of wild-type p53 to the Bcl-2 promoter, preventing Bcl2 binding to and inhibition of proapoptotic Bcl2 family members Bad, Bak and Bax, resulting in apoptosis. 25 Treatment of wild-type and p53-null lymphoblastic leukemia lines with IR demonstrated that downregulation of Bcl2 and subsequent apoptosis are p53-dependent. 26 p73, on the other hand, induces apoptosis by regulating the interaction between Bcl2 and Bax. 27 Although both Mdm2
Tg and Mdm2 Tg ;p73 +/ − mice predominately develop B-cell lymphoma, the latency in tumor development is significantly (Figures 6a and b) . Immunohistochemistry using an antibody against Bcl2 confirms the upregulation of Bcl2 in B-cell lymphomas arising in Mdm2
Tg ;p73 (Figure 6c ). To determine whether this difference in Bcl2 expression affects apoptosis, we used a TdT-mediated dUTP nick-end labeling assay to identify apoptotic cells in B-cell lymphoma sections from Mdm2
Tg and Mdm2 Tg ;p73 +/ − mice. TdT-mediated dUTP nick-end labeling-positive cells were present in the tumors of both genotypes, but the amount of apoptosis is greatly enhanced in the Mdm2
Tg tumors with low expression of Bcl2 (Figure 6c ). These data indicate that loss of p73 in an Mdm2
Tg background results in increased Bcl2 expression and dampened apoptosis in B-cell lymphomas. Taken together, our data support a model by which Mdm2 inhibition of p53 and p73 cooperate in lymphomagenesis via inhibition of apoptosis.
DISCUSSION
Despite the reported physical interaction between Mdm2 and TAp73, no studies to date have addressed the physiological consequences of this interaction. Our data demonstrate that the predominant tumor type found in both Mdm2
Tg and Mdm2
Tg ; p73 +/ − mice is B-cell lymphoma. However, Mdm2 Tg ;p73 +/ − mice develop a higher incidence of B-cell lymphoma and the average time to onset is significantly shorter than observed in Mdm2 Tg and p73 +/ − mice. These data indicate that Mdm2 overexpression alone sensitizes mice to B-cell lymphomagenesis ( Figure 3 ) 7 and that loss of p73 represents an additional event in the pathogenesis, resulting in accelerated tumor development. In order to determine the mechanism underlying the accelerated tumorigenesis in Mdm2
Tg ;p73 +/ − mice, we investigated genomic instability, which is a hallmark of human cancers.
Mdm2 overexpression results in genomic instability in a p53-independent manner, and loss of TAp73 is also linked to genomic instability. Therefore, we investigated and found that loss of even a single copy of p73 in an Mdm2
Tg background results in exacerbated genomic instability. As both Mdm2 Tg ;p73 +/ − and Mdm2 Tg ;p73 − / − MEFS exhibit similar chromosome defects, these data indicate that loss of one copy is sufficient for the phenotype or that the remaining p73 allele is somehow silenced. Previous work 28 and our data (Figure 1 ) demonstrate that MEFs with complete loss of both p73 isoforms are phenotypically normal. However, in the absence of functional p53, p73 is essential for maintaining genome integrity, as evidenced by severe ploidy defects in p53 − / − ;p73 − / − MEFs compared with p53 − / − MEFs. 28 As Mdm2 overexpression results in dampened p53 activity, 28 it is possible that the genomic instability phenotype of Mdm2 
;p73
− / − MEFs, it is likely the observed genomic instability results from a distinct mechanism. Although the exact mechanism of the increased genomic instability is still unknown, these data indicate that the phenotype observed in Mdm2 
pre-malignant B cells from Mdm2
Tg ;p73 +/ − mice exhibit an increase in abnormal metaphases when compared with premalignant Mdm2
Tg B cells, it is possible that this genomic instability sensitizes B cells to lymphomagenesis, resulting in accelerated tumor development and increased tumor incidence.
Another hallmark of human cancers is deregulation of apoptosis by inactivation of proapoptotic tumor suppressors such as p53 or overexpression of antiapoptotic oncogenes such as Bcl-2. Bcl-2 regulates apoptosis in hematological cells, specifically in B cells. As these tumors retain wild-type p53, it is likely that Mdm2 contributes to tumorigenesis in both p53-dependent and independent mechanisms; specifically, it is possible that the accelerated B-cell lymphoma phenotype results from combined loss of p53 and p73 activity and subsequent deregulation of apoptosis. There is some precedent for this as loss of one copy of p73 in a p53 +/ − background results in accelerated lymphoma development and an increase in metastasis. 10 Although these mice predominately develop T-cell lymphoma, it is possible that the early onset of T-cell lymphoma precludes drawing any conclusion as to whether combined p73 and p53 loss results in B-cell lymphoma. To test this hypothesis, we examined protein expression of Bcl-2 in Mdm2
Tg and Mdm2 Tg ;p73 +/ − tumor samples. We chose to examine Bcl2 for several reasons. First, the Bcl2 promoter is downregulated by p53 in human B-cell lymphoma cell lines 25 and mice that lack functional p53 exhibit increased expression of Bcl2 in lymphocytes. 29, 30 Second, the functional domains of p53 that are required for Bcl2 repression are conserved in p73, 31 indicating Bcl2 may be a common target for p53 and p73. Third, overexpression of Mdm2 has been reported in human B-cell lymphomas. 32, 33 Lastly, in the absence of p53, p73 induces apoptosis via regulation of Bax/Bcl2 protein expression. 34 Given that overexpression of Mdm2 dampens p53 activity, 7 it is possible that our mouse model mimics this scenario. Our western blot data indicate that Bcl2 expression is upregulated upon Mdm2 overexpression alone, likely due to Mdm2-mediated p53 degradation and transcriptional inhibition. However, upon p73 loss, Bcl2 expression is further upregulated, indicating that Bcl2 is also elevated downstream of p73 in B cells, although this relationship in B cells warrants further investigation. We performed reverse-phase protein analysis (RPPA) of a small number of lymphomas from Mdm2
Tg
;p73 +/ − mice and did not see a difference in expression of the Bcl2 family members, BAD, BAK1, Bax, or Bcl2L1 (Supplementary Figure 1) , although the sample size was too small for statistical analysis. Given that Bcl2 binds to Bad, Bak and Bax, thus inhibiting apoptosis, expression of these family members in Mdm2
Tg ;p73-deficient B-cell lymphomas should be investigated in more detail. Taken together, these findings address for the first time the physiological consequence of Mdm2 overexpression coupled with p73 loss, which are common events in tumorigenesis. Based on these data, we conclude that Mdm2 overexpression and p73 loss cooperate in B-cell lymphomagenesis through deregulation of genomic stability and apoptosis.
MATERIALS AND METHODS Mice
p73
+/ − mice 10 were backcrossed with C57Bl/6 mice for four generations, making them 99% C57Bl/6. Previously backcrossed Mdm2 transgenics (Mdm2
Tg
; pure C57Bl/6) 6 were mated with p73 +/ − mice 10 to generate Mdm2 Tg ;p73 +/ − mice and non-transgenic littermate controls. At indication of disease, tissues/tumors were collected and frozen, fixed in 10% formalin for paraffin embedding, and a small portion were analyzed by flow cytometry.
Chromosome stability analysis
MEFs were isolated as previously described, 5 cultured for one passage, treated for 4 h with colcemid, harvested and processed for metaphase analysis according to standard protocols at the Molecular Cytogenetics Core Facility at MD Anderson (Houston, TX, USA). In brief, metaphase preparations were stained with PI (Sigma Aldrich, St Louis, MO, USA) and and Mdm2 Tg ;p73 − / − mice were western blotted for Bcl-2 and the loading control Vinculin (2 tumor samples from each genotype). Lysate from a wild-type spleen was used as a control (Lane 1). (b) Quantification of Bcl-2 protein expression as shown in the western blot in (a). Quantification was performed using ImageJ software. Statistical significance between genotypes was calculated by averaging two biological replicates from each genotype followed by two-tailed unpaired Student t-tests. (c) Representative histological sections of B-cell lymphomas subjected to immunohistochemistry using an antibody against mouse Bcl-2 (top two panels) and TdT-mediated dUTP nick-end labeling staining (bottom two panels). Of the 12 lymphomas that arose in Mdm2
Tg mice, 7 were examined by immunohistochemistry to identify the cell of origin and apoptosis. Of the 26 lymphomas that arose in Mdm2
Tg ;p73 +/ − mice, 25 were examined by immunohistochemistry. (Note: the remaining tumors were evaluated using flow cytometry; see Figure 4b ) DAPI (Sigma Aldrich) and mounted with Vectashield (Vector Laboratories, Burlingame, CA, USA) prior to analysis by fluorescent microscopy. Each metaphase was examined for chromosomal aberrations (chromosomal breaks, chromatid breaks and fusions). The total number of chromosomes in each metaphase was counted with computer software. Pure populations of splenic B cells were isolated from pre-malignant (9 months of age) and malignant spleens using the EasySep Mouse B Cell Isolation Kit and EasySep Magnet (StemCell Technologies, Vancouver, BC, Canada). Purified splenic B cells were placed into tissue culture and stimulated with lipopolysaccharide for 48 h prior to harvesting and processing as described above. A portion of the purified cells were used for flow cytometry (see below).
Flow cytometry
Single-cell suspensions from normal and malignant spleen samples were fixed in ethanol and stained with APC-labeled anti-mouse CD45R/B220 (BD Pharmingen, Sparks, MD, USA) and FITC-labeled anti-mouse CD19 (BD Pharmingen) or PE-labeled anti-mouse IgM (BD Pharmingen) to determine the abundant cell type present. Data acquisition was performed at the Flow Cytometry and Cellular Imaging Core Facility at MD Anderson on a FACSCalibur flow cytometer and analysis was performed with FlowJo software (Ashland, OR, USA).
Histological analysis and immunohistochemistry
Sections from paraffin-embedded tissue were dewaxed and rehydrated following standard protocols. Slides were incubated with primary antibody (rat anti-mouse CD45R, BD Pharmingen; rabbit anti-mouse CD3, Abcam (Cambridge, MA, USA); rabbit anti-mouse Bcl-2, Abcam) at a dilution of 1:100 overnight at 4°C. For detection, the Vectastain ABC Kit was used, followed by the Vector Peroxidase Substrate Kit (Vector Laboratories). Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick-end labeling assays were carried out on paraffin-embedded sections according to the manufacturer's specifications (Calbiochem, Darmstadt, Germany). Senescence-associated β-galactosidase (SAβGal) assay was performed essentially as described. 35 Western and Southern blot analysis Spleens or B-cell lymphomas were lysed in RIPA buffer and proteins were western blotted using primary antibodies against mouse Bcl2 (BD Pharmingen), and mouse vinculin (Abcam) at dilutions of 1:1000. Two tumors for each indicated genotype were evaluated for Bcl2 expression as shown in Figure 6a . The analysis was semiquantitative using film with multiple exposures, which were in the linear range. The expression of Bcl2 an d Vinculin from these films was quantified using ImageJ software was developed at NIH (Bethesda, MD, USA). Genomic DNA was isolated from normal control spleen or malignant spleens and lymph nodes and separated on a 0.8% agarose gel and transferred to Hybond-N+ nylon membrane (GE Life Sciences, Little Chalfont, Buckinghamshire, UK). Hybridization was performed in 50% (vol/vol) formamide/SSC at 42°C. The JH4-3 probe was a gift from FW Alt. 36 Analysis for loss of heterozygosity DNA was extracted from frozen tumor tissue and adjacent normal kidney tissue. Genomic DNA was extracted from the tissue with DNAzol reagent (Invitrogen, Grand Island, NY, USA). For detection of p73, PCR was performed using the following primers: Primer 1: 5ʹ-GGGCCATGC CTGTCTACAAAGAA-3ʹ; Primer 2: 5ʹ-CCTTCTACACGGATG AGGTG-3ʹ; Primer 3: 5ʹ-GAAAGCGAAGGAGCAAAGCTG-3ʹ. The wild-type band is 0.650 kb and the mutant band is 0.400 kb.
Reverse-phase protein array
Tumor samples were submitted to the RPPA Core Facility at MD Anderson for analysis using 135 different antibodies. The results were analyzed by the RPPA Core Facility and are provided as Supplementary Figure 1 .
